Table 2 Characterization of population according to acute pancreatitis mortality
Variable | Nonsurvivors (n = 16) | Survivors (n = 166) | pU/pM | aOR, 95%CI in M |
|---|---|---|---|---|
Age (yo), μ ± σ | 71.6 ± 14.3 | 65.8 ± 15.1 | 0.123/− | – |
Male gender, n(%) | 11(68.8%) | 5(53.6%) | 0.245/− | – |
Alcoholism, n(%) | 4(25.0%) | 36(21.7%) | 0.760/− | – |
Smoking, n(%) | 0(0.0%) | 16(9.6%) | 0.481/− | – |
Hospital stay, median(IQR) | 6.5(2–62) | 11.0(2–83) | 0.071/− | – |
Comorbiditiesa, n(%) | 15(93.7%) | 143(86.1%) | 0.391/− | – |
Laboratory and gasometrical parameters | ||||
WBC count (cells/mm3), μ ± σ | 16,810.0 ± 13,490.0 | 1779.1 ± 1214.1 | 0.465/− | – |
AST (IU/L), μ ± σ | 144.6 ± 132.4 | 271.6 ± 198.1 | 0.416/− | – |
ALT (IU/L), μ ± σ | 123.2 ± 100.2 | 227.8 ± 175.4 | 0.116/− | – |
Total bilirubin (mg/dL), μ ± σ | 1.8 ± 1.2 | 2.4 ± 2.3 | 0.869/− | – |
Platelet count (cells/mm3), μ ± σ | 174.4 ± 67.0 | 214.0 ± 80.5 | 0.057/− | – |
BUN (mg/dL), μ ± σ | 35.3 ± 20.1 | 21.9 ± 12.5 | 0.002/− | – |
Creatinine (mg/dL), μ ± σ | 2.2 ± 1.4 | 1.1 ± 0.8 | < 0.001/− | – |
INR, μ ± σ | 1.5 ± 1.0 | 2.1 ± 1.2 | 0.018/− | – |
Albumin (g/dL), μ ± σ | 3.5 ± 0.6 | 3.8 ± 0.7 | 0.074/− | – |
LDH (IU/L), μ ± σ | 465.1 ± 287.8 | 453.9 ± 332.7 | 0.207/− | – |
Serum glucose (mg/dL), μ ± σ | 164.1 ± 104.5 | 147.3 ± 53.2 | 0.945/− | – |
Hemoglobin (mg/dL), μ ± σ | 13.7 ± 3.0 | 13.7 ± 2.0 | 0.889/− | – |
Hematocrit (%), μ ± σ | 41.7 ± 7.5 | 40.7 ± 5.7 | 0.630/− | – |
Serum amylase (IU/L), μ ± σ | 1565.1 ± 1273.3 | 1703.4 ± 1506.4 | 0.391/− | – |
CRP0h (mg/dL), μ ± σ | 10.4 ± 9.6 | 5.9 ± 3.9 | 0.046/− | – |
CRP24h (mg/dL), μ ± σ | 21.8 ± 10.4 | 15.7 ± 10.3 | 0.028/− | – |
Lactate (mg/dL), μ ± σ | 3.6 ± 1.8 | 2.0 ± 1.4 | < 0.001/0.019 | 1.164, [1.003;1.474] |
D-dimers (μg/mL), μ ± σ | 9.1 ± 6.8 | 5.9 ± 4.6 | 0.042/− | – |
Total serum calcium (mg/dL), μ ± σ | 8.0 ± 1.1 | 8.9 ± 1.1 | 0.001/− | – |
RDW0h (%), μ ± σ | 15.3 ± 1.4 | 13.5 ± 1.3 | < 0.001/< 0.001 | 1.038, [1.011;1.087] |
RDW24h (%), μ ± σ | 15.1 ± 1.4 | 13.4 ± 1.6 | < 0.001/0.005 | 1.006, [1.001;1.040] |
RDW0h-to-total serum calcium ratio, μ ± σ | 2.0 ± 0.3 | 1.6 ± 0.3 | < 0.001/< 0.001 | 1.018, [1.007;1.135] |
RDW0h-to-platelets ratio, μ ± σ | 0.10 ± 0.04 | 0.07 ± 0.03 | 0.015/− | |
Prognostic scores | ||||
Ranson score, μ ± σ | 2.7 ± 1.2 | 2.0 ± 1.2 | 0.023/< 0.001 | 1.019, [1.005;1.170] |
BISAP score, μ ± σ | 2.0 ± 1.0 | 1.3 ± 0.8 | 0.003/< 0.001 | 1.010, [1.003;1.059] |
Modified Marshall score, μ ± σ | 1.2 ± 1.0 | 0.6 ± 0.3 | < 0.001/0.020 | 1.109, [1.049;1.169] |